IN2012DN06589A - - Google Patents

Download PDF

Info

Publication number
IN2012DN06589A
IN2012DN06589A IN6589DEN2012A IN2012DN06589A IN 2012DN06589 A IN2012DN06589 A IN 2012DN06589A IN 6589DEN2012 A IN6589DEN2012 A IN 6589DEN2012A IN 2012DN06589 A IN2012DN06589 A IN 2012DN06589A
Authority
IN
India
Prior art keywords
mbl
sepsis
infectious diseases
provides
bind
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Super
Jeffrey Charles Way
Donald E Ingber
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IN2012DN06589A publication Critical patent/IN2012DN06589A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
    • G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
    • G01N27/745—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids for detecting magnetic beads used in biochemical assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Botany (AREA)
IN6589DEN2012 2010-01-19 2011-01-19 IN2012DN06589A (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29622210P 2010-01-19 2010-01-19
PCT/US2011/021603 WO2011090954A2 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment

Publications (1)

Publication Number Publication Date
IN2012DN06589A true IN2012DN06589A (it) 2015-10-23

Family

ID=44307537

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6589DEN2012 IN2012DN06589A (it) 2010-01-19 2011-01-19

Country Status (11)

Country Link
US (7) US9150631B2 (it)
EP (1) EP2526119B1 (it)
JP (5) JP5959440B2 (it)
CN (1) CN102947341B (it)
AU (1) AU2011207626B2 (it)
CA (1) CA2787376A1 (it)
DK (1) DK2526119T3 (it)
ES (1) ES2678143T3 (it)
IN (1) IN2012DN06589A (it)
SG (2) SG10201503351RA (it)
WO (1) WO2011090954A2 (it)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
US8067237B2 (en) 2005-12-13 2011-11-29 President And Fellows Of Harvard College Scaffolds for cell transplantation
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
IN2012DN06589A (it) 2010-01-19 2015-10-23 Harvard College
CA2813751C (en) 2010-10-06 2019-11-12 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US20120241391A1 (en) * 2011-03-25 2012-09-27 Receptors Llc Filtration article with microbial removal, micro-biocidal, or static growth capability
RU2013148071A (ru) * 2011-04-01 2015-05-10 Президент Энд Феллоуз Ов Харвард Колледж Аналогичное диализу терапевтическое (dlt) устройство
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CA2865744A1 (en) * 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
CN107137357B (zh) 2012-04-16 2020-11-24 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
US20130334120A1 (en) * 2012-06-15 2013-12-19 President And Fellows Of Harvard College Fluid cleansing devices and methods of use
EP2875078B1 (en) * 2012-07-18 2017-12-20 President and Fellows of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
EP2976642A4 (en) * 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3022314B1 (en) 2013-07-15 2021-05-19 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
DE102014206444A1 (de) * 2014-04-03 2015-10-08 Siemens Aktiengesellschaft Verfahren für die Molekulardiagnostik zum Anreichern einer Nukleinsäure aus einer biologischen Probe
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3280464A4 (en) 2015-04-10 2018-09-26 President and Fellows of Harvard College Immune cell trapping devices and methods for making and using the same
CN108289928B (zh) * 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
US10265457B2 (en) 2015-09-14 2019-04-23 Medisieve Ltd Magnetic filter apparatus and method
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
WO2017143024A2 (en) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
WO2017201064A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
DK3484448T3 (da) 2016-07-13 2025-06-10 Harvard College Antigenpræsenterende cellemimetiske stilladser og fremgangsmåder til fremstilling og brug af disse
CN109414710B (zh) 2016-07-28 2021-02-05 医疗过滤有限公司 磁力混合器及方法
JP7274214B2 (ja) 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫応答を調節するための生体材料
WO2019064463A1 (ja) * 2017-09-28 2019-04-04 学校法人中部大学 バイオアフィニティーを利用したウイルス又は細菌の濃縮方法及び装置
KR102084688B1 (ko) * 2018-06-18 2020-03-04 울산과학기술원 다중 프로브 혼성화를 이용한 미생물 검출 방법
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN110628624B (zh) * 2019-02-01 2022-07-15 传鸣(宁波)化学科技有限公司 一种磁性微生物捕获材料及微生物捕获方法
CN110294810B (zh) * 2019-06-26 2021-05-04 中国疾病预防控制中心传染病预防控制所 一种含有人IgG1Fc和甘露聚糖结合凝集素C端的重组蛋白
WO2021133963A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Sample preparation and microbial analysis
WO2021133943A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Compositions, devices and methods for diagnosing and treating infectious disease
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
US12390548B2 (en) 2020-05-14 2025-08-19 Mehrdad Michael HOGHOOGHI System and method for protecting a workspace from airborne contaminants
CN111675825B (zh) * 2020-06-09 2022-06-24 大连工业大学 一种附有胰蛋白酶的微孔膜的制备方法及其在蛋白水解中的应用
CA3196472A1 (en) 2020-06-12 2021-12-16 Miraki Innovation Think Tank Llc Lateral flow assay for rapid detection of pathogens in samples
WO2022026800A2 (en) 2020-07-31 2022-02-03 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
US20240199719A1 (en) 2020-08-28 2024-06-20 Miraki Innovation Think Tank Llc Therapeutic compositions comprising microbe-targeting molecules and their use in methods of preventing and treating infectious disease
US20240019435A1 (en) 2020-09-25 2024-01-18 Miraki Innovation Think Tank Llc Compositions, devices and methods comprising microbe-targeting molecules for diagnosing and treating infectious disease
US20230416319A1 (en) 2020-10-01 2023-12-28 Miraki Innovation Think Tank Llc Compositions, devices and methods for identifying, treating and preventing infectious disease using microbe-targeting molecules
WO2022093935A1 (en) 2020-10-27 2022-05-05 Miraki Innovation Think Tank Llc Compositions, systems and methods for pathogen monitoring using microbe-targeting molecules
WO2022125632A1 (en) 2020-12-08 2022-06-16 Miraki Innovation Think Tank Llc Chimeric antigen receptor-expressing cells targeting microbe-associated molecular patterns
WO2022151333A1 (zh) * 2021-01-15 2022-07-21 传鸣(宁波)化学科技有限公司 用于富集微生物的混合物、方法及应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5418198A (en) 1977-07-09 1979-02-09 Toshimitsu Niwa Artificial intraretinal device
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
EP0126772A1 (en) 1982-12-03 1984-12-05 E.I. Du Pont De Nemours And Company Chromogenic support immunoassay
JPS60500548A (ja) 1982-12-03 1985-04-18 イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− 発色性支持体免疫測定法
JPH0718875B2 (ja) 1987-06-19 1995-03-06 ヤマサ醤油株式会社 血中または体液中の微量物質含有量の測定法
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
JP2868777B2 (ja) 1987-08-20 1999-03-10 チルドレンズ・ホスピタル・コーポレイション ヒトマンノース結合タンパク質
ATE122568T1 (de) 1989-01-25 1995-06-15 Commw Scient Ind Res Org Polypeptide, antigene oder vakzine gegen babesiosis.
US5137810A (en) * 1989-04-26 1992-08-11 The University Of North Carolina Method of determining the gram sign of bacteria
DE4018583A1 (de) 1990-06-09 1991-12-12 Henkel Kgaa Modifiziertes verfahren zur direkten herstellung von alkylglykosiden
EP0542833B1 (en) 1990-07-30 1999-09-01 Novartis AG Insecticidal proteins
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
JPH04130274A (ja) 1990-09-20 1992-05-01 Kyoto Ikagaku Kenkyusho:Kk 糖蛋白の分析，検出方法
US5783179A (en) 1991-08-09 1998-07-21 Syntex (U.S.A.) Inc. C-reactive protein fragment with immunomodulatory activity
US5405832A (en) 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
WO1993010799A1 (en) 1991-11-27 1993-06-10 Immtech International Incorporated Method of treating viral infections
US5874238A (en) 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5283238A (en) 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
IT1271486B (it) 1993-10-12 1997-05-28 Italfarmaco Spa Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
WO1997035619A1 (en) * 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US7049099B2 (en) 1998-01-23 2006-05-23 Fuso Pharmaceutical Industries, Ltd. Recombinant human mannan-binding proteins and producing method of the same
JPH11206378A (ja) 1998-01-23 1999-08-03 Fuso Pharmaceutical Industries Ltd 組換えヒトマンナン結合タンパク質およびその製造方法
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
ID27972A (id) 1998-07-31 2001-05-03 Asahi Chemical Ind Antibodi-antibodi untuk mendeteksi berbagai mikroorganisme
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PT1181363E (pt) 1999-05-14 2007-05-31 Steffen Thiel Lectina de ligação a manano humana recombinante.
CA2379388C (en) * 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US6503761B1 (en) 1999-10-19 2003-01-07 Kimberly-Clark Worldwide, Inc. Selective removal of contaminants from a surface using articles having magnets
CA2399832C (en) * 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
JP2002165591A (ja) 2000-09-25 2002-06-11 Jsr Corp 磁性粒子およびその使用方法
WO2002032292A2 (en) 2000-10-18 2002-04-25 The Board Of Trustess Of The Leland Stanford Junior University Methods for development and use of diagnostic and therapeutic agents
GB0119274D0 (en) 2001-08-08 2001-10-03 Univ Durham Fusion proteins for insect control
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
WO2003054164A2 (en) * 2001-12-19 2003-07-03 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
US6844426B2 (en) 2002-02-06 2005-01-18 Toyo Boseki Kabushiki Kaisha Magnetic carrier capable of binding with protein and purification method of protein utilizing the magnetic carrier
EP1478393A4 (en) 2002-02-07 2006-02-08 Massachusetts Inst Technology ANTI-PATHOGENIC TREATMENTS
JP2005526084A (ja) 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
US20030180814A1 (en) 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
JP2005523336A (ja) 2002-04-24 2005-08-04 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ マンノース結合レクチン及びその使用方法
US20040018611A1 (en) 2002-07-23 2004-01-29 Ward Michael Dennis Microfluidic devices for high gradient magnetic separation
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
BR0313650A (pt) * 2002-08-20 2007-08-14 Genitrix Llc composição, vetor de expressão, composição de vacina e uso
EP1539964B1 (en) 2002-09-10 2006-12-27 Natlmmune A/S Collectin-complement activating protein chimeras
GB2393728A (en) 2002-10-04 2004-04-07 Nanomagnetics Ltd Magnetic nanoparticles
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
RU2353399C2 (ru) 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DE10325752A1 (de) 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
EP1678197A4 (en) 2003-10-24 2008-05-07 Ludwig Inst Cancer Res METHOD AND COMPOSITION FOR ACTIVATING INHIBITION OF PDGF-C
DK1699821T3 (da) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
SE0401033D0 (sv) 2004-04-20 2004-04-20 Amersham Biosciences Ab Device and method for protein analysis
WO2007001332A2 (en) 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
US20090269843A1 (en) 2004-08-20 2009-10-29 Novo Nordisk A/S Hemopexin fusion proteins
DK1800136T3 (da) 2004-10-15 2012-03-26 Danisco Us Inc Kompetitiv differentiel screening
WO2006046786A1 (en) 2004-10-28 2006-05-04 Dobeel Co., Ltd. Method for the mass production of multimeric mannose binding lectin
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7172906B2 (en) 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
US8084275B2 (en) 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
WO2006108417A2 (en) 2005-04-11 2006-10-19 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions associated with cancer
US20070031819A1 (en) 2005-04-26 2007-02-08 University Of Washington Microfluidic systems for biological and molecular analysis and methods thereof
CN101237857A (zh) 2005-05-09 2008-08-06 生物领域医疗公司 使用微球和非离子型造影剂的组合物和方法
US20070231833A1 (en) 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
JP4423394B2 (ja) * 2005-06-17 2010-03-03 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
TWI333959B (en) 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
AU2006299414A1 (en) 2005-09-30 2007-04-12 Caliper Life Sciences, Inc. Microfluidic device for purifying a biological component using magnetic beads
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
US8013120B2 (en) 2005-10-26 2011-09-06 Stc.Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
US20070269818A1 (en) 2005-12-28 2007-11-22 Affymetrix, Inc. Carbohydrate arrays
US20090181041A1 (en) 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
CN101415813B (zh) 2006-02-03 2013-04-10 微芯片生物工艺学股份有限公司 微流体装置
WO2007111938A2 (en) 2006-03-23 2007-10-04 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
EP1862541A1 (en) 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
KR101343034B1 (ko) 2006-09-05 2013-12-18 삼성전자 주식회사 원심력 기반의 단백질 검출용 미세유동 장치 및 이를포함하는 미세유동 시스템
US8273310B2 (en) 2006-09-05 2012-09-25 Samsung Electronics Co., Ltd. Centrifugal force-based microfluidic device for nucleic acid extraction and microfluidic system including the microfluidic device
US8088596B2 (en) * 2006-10-10 2012-01-03 Oakland University Method of microorganism detection using carbohydrate and lectin recognition
WO2009008925A2 (en) 2007-04-05 2009-01-15 The Regents Of The University Of California A particle-based microfluidic device for providing high magnetic field gradients
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008130618A1 (en) 2007-04-19 2008-10-30 The Charles Stark Draper Laboratory, Inc. Method and apparatus for separating particles, cells, molecules and particulates
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
US7867491B2 (en) 2007-05-30 2011-01-11 Genexine Co., Ltd. Immunoglobulin fusion proteins
EP2197464A2 (en) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
KR20100087344A (ko) 2007-10-29 2010-08-04 버지니아 테크 인터렉추얼 프라퍼티스, 인크. 돼지 ＤＣ-ＳＩＧＮ, ＩＣＡＭ－３ 및 ＬＳＥＣｔｉｎ 및 이의 용도
US20110027267A1 (en) 2007-11-09 2011-02-03 Anaphore, Inc. Fusion Proteins of Mannose Binding Lectins for Treatment of Disease
ES2326109B1 (es) 2007-12-05 2010-06-25 Consejo Superior De Investigaciones Cientificas Microdispositivo de separacion y extraccion selectiva y no invasiva de particulas en suspensiones polidispersas, procedimiento de fabricacion y sus aplicaciones.
WO2009078015A2 (en) 2007-12-18 2009-06-25 Procognia (Israel) Ltd Method and assay for glycosylation pattern detection related to cell state of stem cells
WO2009086343A2 (en) 2007-12-31 2009-07-09 3M Innovative Properties Company Microorganism-capturing compositions and methods
WO2009126346A2 (en) 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
WO2009119722A1 (ja) 2008-03-28 2009-10-01 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
CN101983238B (zh) 2008-03-31 2013-06-12 日本烟草产业株式会社 病毒浓缩方法
AU2009232597A1 (en) 2008-03-31 2009-10-08 Japan Tobacco Inc. Quantitation method of virus
US20100323429A1 (en) 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
US8865876B2 (en) 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity
EP2303306A4 (en) 2008-06-03 2012-08-22 Stc Unm DEVELOPMENT OF A C REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC UTILITY IN IMMUNO THROMBOCYTOPENIA AND LUPUS NEPHRITIS
JP2010122205A (ja) 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
WO2010028306A2 (en) 2008-09-05 2010-03-11 The Regents Of The University Of California Office Of The President Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
WO2010065765A2 (en) 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
US8470555B2 (en) 2008-12-22 2013-06-25 National University Corporation Hokkaido University Protein substance having triple helix structure and manufacturing method therefor
EP2829550B1 (en) * 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
WO2010088261A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Binding-site modified lectins and uses thereof
US20130012451A1 (en) 2009-12-21 2013-01-10 The Research Foundation Of State University Of New York Compositions and methods for inhibiting mmp-9-mediated cell migration
IN2012DN06589A (it) 2010-01-19 2015-10-23 Harvard College
WO2011091037A2 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Rapid pathogen diagnostic device and method
US9353646B2 (en) 2011-01-19 2016-05-31 President And Fellows Of Harvard College Slippery surfaces with high pressure stability, optical transparency, and self-healing characteristics
RU2013148071A (ru) 2011-04-01 2015-05-10 Президент Энд Феллоуз Ов Харвард Колледж Аналогичное диализу терапевтическое (dlt) устройство
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof

Also Published As

Publication number Publication date
US20200095300A1 (en) 2020-03-26
DK2526119T3 (en) 2018-07-30
US11203623B2 (en) 2021-12-21
US20200299345A1 (en) 2020-09-24
US9150631B2 (en) 2015-10-06
JP2017014194A (ja) 2017-01-19
JP5959440B2 (ja) 2016-08-02
CN102947341B (zh) 2018-07-06
US20200291083A1 (en) 2020-09-17
US20130035283A1 (en) 2013-02-07
US10538562B2 (en) 2020-01-21
SG10201503351RA (en) 2015-06-29
US20180094035A1 (en) 2018-04-05
WO2011090954A3 (en) 2012-01-12
EP2526119B1 (en) 2018-05-30
JP2019142901A (ja) 2019-08-29
CN102947341A (zh) 2013-02-27
EP2526119A2 (en) 2012-11-28
AU2011207626B2 (en) 2015-06-18
CA2787376A1 (en) 2011-07-28
WO2011090954A2 (en) 2011-07-28
AU2011207626A2 (en) 2012-10-04
JP2022097536A (ja) 2022-06-30
US20220056089A1 (en) 2022-02-24
EP2526119A4 (en) 2013-10-02
JP6960957B2 (ja) 2021-11-05
JP2013517327A (ja) 2013-05-16
JP7062723B2 (ja) 2022-05-06
SG182577A1 (en) 2012-08-30
JP6513604B2 (ja) 2019-05-15
JP2020193201A (ja) 2020-12-03
US11059874B2 (en) 2021-07-13
US11059873B2 (en) 2021-07-13
ES2678143T3 (es) 2018-08-09
AU2011207626A1 (en) 2012-08-09
US20160200785A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
IN2012DN06589A (it)
CY1122191T1 (el) Βακτηριο για χρηση ως προβιοτικο για διατροφικες και ιατρικες εφαρμογες
Whibley et al. Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species
CY1124488T1 (el) Απελευθερωση πρωτεϊνης που βασιζεται σε εξασθενημενης λοιμογονικοτητας βακτηριδια
MX2011011331A (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas.
EA201491656A1 (ru) Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения
EP3912986A3 (en) Crp capture/detection of bacteria
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2015021390A3 (en) Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA201001212A1 (ru) Лечение микробных инфекций
MX366858B (es) Composicion farmaceutica que comprende un complejo de carga con portador polimerico y al menos y un antigeno proteinico o peptidico.
BR112014023005A2 (pt) diagnóstico rápido e tratamentos personalizados para acne
EA201491481A1 (ru) Аллергены тимофеевки луговой и способы и применения для модулирования иммунного ответа
BRPI0708101A8 (pt) anticorpos contra a il-22 humana e usos para eles
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
BR112017004059A2 (pt) dispositivo de hemoperfusão utilizável
EP2739244A4 (en) SYSTEMS, METHODS, AND IMPLANTS FOR TREATING PROLAPS OR INCONTINENCE
MX2011004483A (es) Leucolectinas y sus usos.
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas
MX2019006620A (es) Composiciones de polisacaridos y metodos de uso.
EP4597105A3 (en) Methods and systems for the detection and removal of pathogens from blood
BR112019002039A2 (pt) anticorpos anti-o2 e uso dos mesmos